KeyBanc Raises Price Target for American Healthcare REIT
Recently, KeyBanc Capital Markets increased its price target for American Healthcare REIT, Inc (NYSE: AHR) to $28, up from $27, while keeping an Overweight rating on the stock. This change comes after the company announced a larger follow-on common equity offering aimed at acquiring the remaining interest in Trilogy Holdings. This strategic step also aims to facilitate the repayment of current debt.
Growth Prospects Amid Transitions
The analyst noted that this transaction is expected to generate returns in the high-single-digit percentage range based on the projected net operating income (NOI) for the second quarter of 2024. Importantly, this estimate is seen as conservative compared to the actual first-year NOI achieved. Moreover, the analyst foresees that the transaction’s benefits may exceed previous projections, suggesting a boost in profitability.
Annualized Impact on Funds From Operations
KeyBanc estimates that the equity offering and related transaction will contribute approximately $0.11 per share to American Healthcare REIT's normalized funds from operations (NFFO) on an annualized basis. Consequently, they have upped their 2025 NFFO estimate to $1.52 per share, a revision from the prior forecast of $1.41 per share, while leaving the 2024 NFFO estimate steady at $1.28 per share.
Clarifying Future Investments
The completion of this transaction is expected to clarify American Healthcare REIT's business model, paving the way for future investments and acquisitions within the Trilogy network. Additionally, this move aims to reduce the company's net debt to EBITDA ratio by about 0.5x, positioning it in the low-to-mid 5x range.
Opportunities for Expansion
With improved financing conditions and lowered leverage, KeyBanc points out that American Healthcare REIT is now in a stronger position to explore external growth opportunities. This strategy could significantly enhance growth and diversify the company’s portfolio, including new operators, different geographic regions, and various business segments. The revised price target of $28 reflects the anticipated positive impact of these recent transactions.
Recent Developments and Market Reaction
In other news, American Healthcare REIT recently initiated a public offering of 14.5 million shares of common stock. The proceeds from this offering will be used to finance the acquisition of the remaining 24% minority interest in Trilogy Holdings, LLC, and to help repay debts related to its credit facilities. Additionally, the company projects a 3.3% growth in 2024 Normalized Funds From Operations (FFO) as well as a significant increase in same-store net operating income (SSNOI) in the upcoming year.
Analyst Ratings and Market Sentiment
Several financial institutions have also adjusted their price targets for American Healthcare REIT. Truist Securities recently set their target at $27, reflecting the implications of the recent equity offering and the expected execution of the Trilogy purchase option. At the same time, BofA Securities significantly raised their price target from $19 to $27 while maintaining a positive outlook on the stock.
Analysts from various firms, including Barclays Capital Inc., JMP Securities, KeyBanc, and RBC Capital Markets, have assigned American Healthcare REIT an Overweight rating, highlighting its strategic standing within the healthcare real estate sector.
InvestingPro Insights on Financial Performance
Market insights suggest that American Healthcare REIT, Inc's financial outlook and market performance are looking hopeful. With a market capitalization of $3.47 billion as of the last twelve months leading into Q2 2024, the revenue growth rate of 9.24% indicates continued potential, even though the company has a negative P/E ratio of -59.07, reflecting its current unprofitability.
Future Growth and Investor Confidence
InvestingPro indicates that net income growth is expected for American Healthcare REIT, aligning with analyst forecasts for advantageous transactions. The stock has recently shown impressive performance, boasting a 71.58% return over the past three months and an impressive year-to-date total return of 92.03%. This suggests that investor confidence is on the rise. However, the stock’s currently elevated EBIT valuation multiple indicates it might be overbought according to the RSI, calling for careful investment evaluation.
Frequently Asked Questions
What is the new price target for American Healthcare REIT?
KeyBanc has increased the price target for American Healthcare REIT to $28 from $27.
What will the proceeds from the equity offering be used for?
The funds from the equity offering are designated for acquiring the remaining interest in Trilogy Holdings and repaying current debt.
How have other analysts modified their projections?
Other financial firms, such as Truist and BofA Securities, have adjusted their price targets, with BofA's target rising from $19 to $27.
Why is there optimism in the market regarding American Healthcare REIT?
The optimism rests on expected profitable transactions and growth opportunities through acquisitions, which should enhance portfolio diversity.
What financial indicators reflect American Healthcare REIT's condition?
The company possesses a market capitalization of $3.47 billion and a revenue growth rate of 9.24%, though it's currently unprofitable with a negative P/E ratio.
